Abstract: The present invention relates to a composition comprising ethyl vanillin or a pharmaceutically acceptable salt thereof as an effective ingredient for preventing or treating muscle disease or for improving a muscle function. Having the capability of upregulating the expression of a protein associated with muscle protein synthesis and muscle mass increase in myocytes and downregulating at an mRNA level the expression of an enzyme involved in muscle protein degradation, ethyl vanillin can exhibit effects of muscle differentiation, muscle regeneration, and muscle strengthening through an increase in muscle mass against muscle diseases attributed to muscle function decrease, muscle consumption, or muscle degradation and can suppress sarcopenia. Thus, ethyl vanillin can be used for preventing or treating muscle diseases or for promoting muscle differentiation, muscle regeneration and muscle strengthening, muscle mass increase, or muscle generation or for improving muscle function.
Type:
Grant
Filed:
July 17, 2018
Date of Patent:
February 14, 2023
Assignee:
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Abstract: The invention relates to the therapy of diseases associated with the activity of histamine receptors, in particular for the treatment of allergic diseases, preferably the therapy of perennial and persistent allergic rhinitis, itch, as well as a number of other diseases associated with the activity of histamine receptor type 3 and/or 4, using compound N,N?-bis(2-(1H-imidazol-5-yl)ethyl)malonamide. This compound, as well as pharmaceutically acceptable salts, hydrates, or solvates thereof, is an antagonist of histamine receptor type 3 and/or 4. The invention also relates to pharmaceutical compositions containing a therapeutically effective amount of Compound I.
Abstract: The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.
Abstract: The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.
Type:
Grant
Filed:
September 30, 2020
Date of Patent:
January 31, 2023
Assignee:
Neoculi Pty Ltd
Inventors:
Stephen Page, Andrew Stevens, Adam McCluskey, Martine Keenan, Rebecca Abraham
Abstract: Dental treatments and methods, including treating gum disease, using peroxide gel and a viscous antibacterial agent including tetracycline to chemically debride and curettage a treatment area. Treatments and methods include non-surgically scaling and root plaining the treatment area with dental tools such as periodontal scalers and/or curettes during the active period of the chemical debridement. The working surfaces of dental tools can be sharpened for optimal root and tooth surfacing during treatment. Treatment can include instructions for co-therapy by or on behalf of treatment subjects between visits and for maintenance care.
Abstract: The instant invention is related to a novel solid form of ceftolozane sulfate (the DMAc solvate of ceftolozane sulfate (Form 3)), compositions comprising ceftolozane sulfate DMAc solvate (Form 3), synthesis of Form 3 and an improved crystallization process using Form 3 to prepare ceftolozane sulfate Form 2. Novel compositions also include ceftolozane sulfate solid Form 3 and/or other crystalline and amorphous solid forms of ceftolozane.
Type:
Grant
Filed:
June 1, 2017
Date of Patent:
January 3, 2023
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Kevin Matthew Maloney, Eric M. Sirota, Richard J. Varsolona, Donald R. Gauthier, Jr., Hong Ren
Abstract: The present disclosure relates to compositions including a fatty acid soap/fatty acid mixture, and methods of use thereof. The compositions include a C5 to C12 fatty acid or mixtures thereof. The compositions show increased activity, e.g., insecticidal, soil removal, antimicrobial activity, at a controlled pH range of about 7.5 to about 9.0.
Type:
Grant
Filed:
March 20, 2018
Date of Patent:
December 27, 2022
Assignee:
Ecolab USA Inc.
Inventors:
Victor Fuk-Pong Man, Yvonne Marie Killeen, Michael Charles DeNoma, Kelly J. Herrera, S. John Barcay, William J. Pattison
Abstract: This invention relates to the use of at least one following compound having formula (I), as well as the salts thereof, the optical and geometric isomers thereof, and the solvates thereof, as deodorant agent for treating body odor, preferably underarm odor:
Abstract: Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD).
Abstract: Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated arachidonic acid or an ester thereof.
Type:
Grant
Filed:
August 20, 2021
Date of Patent:
November 29, 2022
Assignee:
Retrotope, Inc.
Inventors:
Peter Milner, Mikhail Sergeevich Shchepinov
Abstract: Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.
Abstract: Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated linoleic acid or an ester thereof.
Type:
Grant
Filed:
August 2, 2021
Date of Patent:
November 8, 2022
Assignee:
Retrotope, Inc.
Inventors:
Peter Milner, Mikhail Sergeevich Shchepinov
Abstract: The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.
Type:
Grant
Filed:
November 15, 2019
Date of Patent:
November 8, 2022
Assignee:
Nimbus Artemis, Inc.
Inventors:
Silvana Marcel Leit de Moradei, Kevin Kreutter, H. James Harwood, Eric Therrien
Abstract: The disclosure relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., diabetes mellitus, chronic kidney disease, acute kidney failure, and reduction of blood glucose levels.
Type:
Grant
Filed:
May 22, 2018
Date of Patent:
November 8, 2022
Assignee:
INTRA-CELLULAR THERAPIES, INC.
Inventors:
Peng Li, Youyi Peng, Lawrence P. Wennogle, Qiang Zhang
Abstract: The present invention provides a compound that have excellent harmful arthropod controlling effects, the compounds being represented by formula (I) [wherein R represents a C1-C6 chain hydrocarbon group etc., X represents a C1-C4 chain hydrocarbon group etc., G represents a C1-C4 chain hydrocarbon group etc., and n is 0, 1, 2, or 3], as well as a composition for controlling harmful arthropod comprising the same, and a method for controlling harmful arthropod comprising applying the same.
Abstract: Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.
Type:
Grant
Filed:
May 20, 2020
Date of Patent:
November 8, 2022
Assignee:
Gilead Sciences, Inc.
Inventors:
Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dorothy Agnes Theodore
Abstract: This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases.
Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.
Type:
Grant
Filed:
May 22, 2020
Date of Patent:
November 1, 2022
Assignee:
LUMOS PHARMA, INC.
Inventors:
Mario Mautino, Sanjeev Kumar, Firoz Jaipuri, Jesse Waldo, Hima Potturi, Hong Zhuang
Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Type:
Grant
Filed:
December 19, 2019
Date of Patent:
October 25, 2022
Assignee:
ESTEVE PHARMACEUTICALS, S.A.
Inventors:
Carlos-Ramón Plata-Salaman, Nicolas Tesson